ArticleBMC gastroenterology2026
Risk factors and development of a predictive model for chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimTo identify risk factors for chronic kidney disease (CKD) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and to develop a risk prediction model for CKD comorbidity within this population, thereby facilitating targeted prevention and early screening.
methodsWe retrospectively enrolled 8,975 MASLD patients diagnosed by color Doppler ultrasonography at the Affiliated Hospital of Nantong University between 2021 and 2023. Participants were categorized into CKD and non-CKD groups based on standard diagnostic criteria. Baseline biochemical parameters, including markers of glucose, lipid metabolism, inflammation, and organ function, were compared between two groups. Independent predictors were identified using multivariable logistic regression and incorporated into a nomogram. Model performance was temporally validated in an independent MASLD cohort from 2024 via receiver operating characteristic (ROC) curve analysis, calibration plots, and decision curve analysis (DCA).
resultsCompared with the non-CKD group, the CKD group exhibited significantly higher levels of systolic blood pressure, creatinine, triglycerides, and uric acid to high-density lipoprotein cholesterol ratio, but lower hemoglobin compared with the non-CKD group (P < 0.05). Age, systolic blood pressure, hemoglobin, triglycerides, and uric acid to high-density lipoprotein cholesterol ratio were identified as independent predictors of MASLD with CKD. The developed nomogram exhibited strong discriminative power, consistent calibration during temporal validation, and demonstrated favorable net benefit across clinically relevant threshold probabilities in the DCA.
conclusionThe accurate estimation of CKD risk in patients with MASLD is effectively achieved via a nomogram incorporating routinely available clinical indicators, thereby facilitating early screening and individualized interventions for high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.